Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.38 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.38 |
| ▸ | CPA3 | P15088 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | GFER | P55789 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | FNTA | P49354 | 1/20 | 0.37 |
| ▸ | FNTB | P49356 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4026649 | 0.84 | KMT2A (0.46) | MAPTHTTSMN1; SMN2LTA4HMEN1 | |
| SCHEMBL5508265 | 0.83 | CPA3 (0.57) | CYP1A2TSHRCPA3GAA | |
| SCHEMBL10765112 | 0.80 | MAPK1 (0.57) | MAPTSMN1; SMN2MEN1KMT2ATSHR | |
| SCHEMBL5514976 | 0.79 | MAPT (0.48) | MAPTHTTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL5513749 | 0.79 | PTGER1 (0.49) | CYP1A2TSHRCPA3GAA | |
| SCHEMBL11019050 | 0.79 | MEN1 (0.56) | MAPTCYP1A2HTTSMN1; SMN2MEN1 | |
| SCHEMBL5523832 | 0.79 | CPA1 (0.55) | MAPTCYP1A2HTTSMN1; SMN2LTA4H | |
| SCHEMBL12942805 | 0.77 | MAPT (0.56) | MAPTHTTSMN1; SMN2HRH1MEN1 | |
| SCHEMBL3198336 | 0.74 | ALPI (0.52) | MAPTLTA4HSLC1A2SLC1A1 | |
| SCHEMBL1339972 | 0.74 | ALPI (0.52) | MAPTLTA4HSLC1A2SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1261601-B1 | SUBSTITUTED INDOLES FOR MODULATING NFKB ACTIVITY | SANOFI AVENTIS DEUTSCHLAND (DE) | 2009-07-29 | — | — | EP | disclosed |
| US-7342029-B2 | 2,3-Diphenyl-1H-indole-5-carboxylic acid; I kappa B kinase inhibitor; decrease activation of nuclear factor (NF) kappa B; antiinflammatory agent: arthritis, osteoarthritis, asthma, cardiac infarct, Alzheimer's disease, carcinomateous disorders or atherosclerosis | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-03-11 | — | — | US | disclosed |
| US-20050282866-A1 | 2,3-Diphenyl-1H-indole-5-carboxylic acid; I kappa B kinase inhibitor; decrease activation of nuclear factor (NF) kappa B; antiinflammatory agent: arthritis, osteoarthritis, asthma, cardiac infarct, Alzheimer's disease, carcinomateous disorders or atherosclerosis | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-12-22 | — | — | US | disclosed |
| EP-1194425-B1 | SUBSTITUTED BENZIMIDAZOLE | AVENTIS PHARMA GMBH (DE) | 2005-08-10 | — | — | EP | disclosed |
| US-20040209868-A1 | Substituted indoles | AVENTIS PHARMA DEUTSCHLAND GMBH | 2004-10-21 | — | — | US | disclosed |
| US-20030119820-A1 | Therapy of disorders resulting from increased activity of nuclear factor kappa-beta | AVENTIS PHARMA DEUTSCHLAND GMBH | 2003-06-26 | — | — | US | disclosed |
| EP-1261601-A1 | SUBSTITUTED INDOLES FOR MODULATING NFKB ACTIVITY | Aventis Pharma Deutschland GmbH (DE) | 2002-12-04 | — | — | EP | disclosed |
| EP-1194425-A1 | SUBSTITUTED BENZIMIDAZOLE | Aventis Pharma Deutschland GmbH (DE) | 2002-04-10 | — | — | EP | disclosed |
| US-6358978-B1 | FOR THERAPY AND PROPHYLAXIS OF RHEUMATOID ARTHRITIS (IN THE CASE OF INFLAMMATION), OSTEOARTHRITIS, ASTHMA, CARDIAC INFARCT, ALZHEIMER'S DISEASE, OR ATHEROSCLEROSIS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-03-19 | — | — | US | disclosed |
| WO-2001030774-A1 | SUBSTITUTED INDOLES FOR MODULATING NFKB ACTIVITY | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-05-03 | — | — | WO | disclosed |
| WO-2001000610-A1 | SUBSTITUTED BENZIMIDAZOLE | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209868-A1 | Substituted indoles | NFKBIA, IKBKG, IKBKB | MAPT 1339/4885CYP1A2 68/4885HTT 1823/4885 |
| US-20030119820-A1 | Therapy of disorders resulting from increased activity of nuclear factor kappa-beta | NFKBIA, NFKB1, NFKB2 | MAPT 2154/4885CYP1A2 892/4885HTT 2624/4885 |
| US-20050282866-A1 | 2,3-Diphenyl-1H-indole-5-carboxylic acid; I kappa B kinase inhibitor; decrease activation of nuclear factor (NF) kappa B; antiinflammatory agent: arthritis, osteoarthritis, asthma, cardiac infarct, Alzheimer's disease, carcinomateous disorders or atherosclerosis | NFKBIA, IKBKB, IKBKE | MAPT 455/4885CYP1A2 2405/4885HTT 1823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.